Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn:

“I’m sharing our recently published review addressing a long-standing question in pancreatic cancer research: why an oncogenic KRAS mutation is not sufficient, on its own, to induce and sustain malignant transformation.

In PDAC, KRAS mutations are almost universal, yet tumor initiation and progression depend on the biological and genetic context in which KRAS operates. This review brings together mechanistic, experimental and translational studies showing how cooperative alterations (tumor suppressors, telomerase, MYC, microenvironmental cues) are required to overcome senescence and enable malignancy.

We hope this work contributes to a clearer framework for understanding KRAS-driven cancers and helps support ongoing discussion around more rational, context-aware therapeutic strategies in translational research.”

Title: Why isn’t an oncogenic mutation in KRASenough to induce and sustain transformation?